Persons with haemophilia (PWH) experience spontaneous or traumarelated bleedings, most commonly joint bleeds, which progressively lead to swelling, limitation of movement, cartilage destruction and haemophilic arthropathy.
In patients with severe haemophilia B the prevalence of inhibitors is around 3%. 8 The ultimate goal of treatment in patients with inhibitors is immune tolerance induction (ITI); however, during the induction phase of ITI, when ITI fails and where ITI is not affordable, the treatment of bleeding becomes a relevant objective. The goals in the treatment of bleeding episodes are to relieve pain and to prevent, or at least slow down, the progression towards arthropathy caused by recurrent bleeding into the joint. Aggressive treatment of acute bleeds should be considered, including the use of higher and repeated-dose regimens until complete resolution of the bleed. 9, 10 For patients with high-responding, high-titre inhibitors and acute bleeding, bypassing agents -recombinant activated factor VII (rFVIIa) and plasma-derived activated prothrombin complex concentrate (aPCC) -are the gold standard. 7, 8 
Evidence of Efficacy
There are several literature reports about the efficacy and safety of bypassing agents for treatment of bleeding in haemophilia patients with inhibitors. The evidence base has been systematically reviewed using two approaches by Iorio et al. 12 and Treur et al. 13 Iorio et al. summarised the evidence from the two available head-to-head crossover multicentre randomised controlled trials, 14, 15 concluding that rFVIIa and aPCC were found to be similar in efficacy Treur et al. 13 provided a comprehensive appraisal of all the available randomised and non-randomised evidence from 17 studies and 382 patients treated with rFVIIa and 317 treated with aPCC, 11,15-24 using a Bayesian approach to predict the likelihood of response 12, 24 and 36 hours after three-hourly 90μg/kg rFVIIa or 75IU/kg aPCC. The results showed rFVIIa to be the dominant strategy with a 66, 88
and 95% likelihood of response, respectively, the results being consistent at several sensitivity analyses.
The feasibility of front-loaded treatment with 270μg/kg rFVIIa was further demonstrated by Kavakli et al. 20 and Santagostino et al. 22 Patients were randomly allocated by Kavakli et al. 20 to have a first joint bleeding episode treated with one 270μg/kg rFVIIa dose followed by two doses of placebo at three-hour intervals and a second joint bleed with three single doses of 90μg/kg rFVIIa at three-hour intervals, or vice versa. Treatment was rated as effective for 65% of patients using the 270μg/kg dose versus 70% for the three × 90μg/kg regimen. 
Conclusion
The systematic appraisal of the available evidence showed that most bleeding episodes in haemophilia patients with inhibitors can be successfully treated with rFVIIa or aPCC. The recombinant drug seems to provide a more favourable benefit-risk ratio and may be easily administered as a single front-loaded bolus, making it a good candidate for the role of first-line treatment for bleeding in patients with inhibitors. n Recombinant Factor VIIa Concentrate for the Treatment of Acute Bleeding Episodes
